Antibody-based immunotherapies targeting the malignant plasma cell-specific antigens CD38, CD138, BCMA, FcRH5, and GPRC5D have demonstrated a safety profile, with mainly low-grade cytokine release syndrome, cytopenias, and infections [40, 41]. Here, FCRL5 is linked to infection.